Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance

Menopause

Volumn 17, Issue 6, 2010, Pages 1099-1103

  Mueck, Alfred O ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; ESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PREGNANE DERIVATIVE;

ACTIVATED PROTEIN C RESISTANCE; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM COMPARISON; EDITORIAL; GENE MUTATION; GROUPS BY AGE; HORMONAL THERAPY; HUMAN; OBESITY; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; CONTRACEPTIVES, ORAL, COMBINED; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; PROGESTINS; VENOUS THROMBOEMBOLISM;

EID: 78649657583     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181fa264c     Document Type: Editorial

References (56)

1. Young RL, Goepfert AR, Goldzieher HW. Estrogen replacement therapy is not conducive of venous thromboembolism. Maturitas 1991;13:189-192.
2. Saleh AA, Dorey LG, Dombrowski MP, et al. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993;169:1554-1557.
3. Jick H, Derby L, Myers MW, et al. Risk of hospital admission for idio-pathic venous thromboembolism among users of postmenopausal oes-trogens. Lancet 1996;348:981-983.
4. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-980.
5. Perez Gutthann S, Rodriguez LAG, Castellsague J, Oliart AD. Hormone replacement therapy and the risk of venous thromboembolism: population-based case-control study. Br Med J 1997;314:796-800.
6. Grady D, Wenger NK, Herrington D, et al; for the Heart and Estrogen/Progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000;132: 689-696.
7. Cushman M, Kuller LH, Prentice R, et al; for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580.
8. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166: 772-780.
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002;288:321-333.
10. LaCroix AZ. Estrogen with and without progestin: benefits and risks of short-term use. NIH State-of-the-Science Conference on Management of Menopause-Related Symptoms, Bethesda, MD, March 2005:73-79. http://www.ahrq.gov/ clinic/epcsums/menosum.pdf. Accessed March 10, 2005.
11. Vickers MR, MacLennan AH, Lawton B, et al; WISDOM group. Main morbidities recorded in the Women's International Study of Long Duration Oestrogen After Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239.
12. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (Study Group). Lancet 1995; 346:1582-1588.
13. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995;346: 1589-1593.
14. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 1995;346:1593-1596.
15. Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999;5:721-735.
16. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous throm-boembolism. Contraception 1997;56:141-146.
17. Lewis MA, MacRae KD, Kühl-Habichl D, et al. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999;14:1493-1499.
18. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-88.
19. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998;57:291-301.
20. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323: 131-134.
21. European Medicines Agency (EMEA). Committee for Proprietary Medicinal Products (CPMP). CPMP public assessment report: combined oral contraceptives and venous thromboembolism. London: England, September 28, 2001. EMEA/CPMP/2201/01/en/Final.
22. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321: 1190-1195.
23. Farmer RD, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database. BMJ 2000;321:477-479.
24. Skegg DC. Pitfalls of pharmacoepidemiology. BMJ 2000;321:1171-1172.
25. Drife JO. The third generation pill controversy (Bcontinued[). BMJ 2001;323:119-120.
26. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
27. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombo-philia Study. Lancet 1993;342:1503-1506.
28. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522. (Pubitemid 24058953)
29. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
30. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-1276.
31. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembo-lism. Ann Intern Med 1999;130:643-650.
32. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-1307.
33. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-619.
34. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457.
35. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol 1997;97: 233-238.
36. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122:465-470.
37. Rosing J, Middeldorp S, Curvers J, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999;354:2036-2040.
38. Kluft C, de Maat MP, Heinemann LA, et al. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999;354: 832-833.
39. Kemmeren JM, Algra A, Meijers JC, et al. Effect of second-and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004;103:927-933.
40. Van Rooijen M, Silveira A, Hamsten A, Bremme K. Sex hormoneY binding globulinVa surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 2004;190:332-337.
41. van Vliet HA, Frolich M, Christella M, et al. Association between sex hormoneYbinding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005;20:563-568.
42. van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:2060-2062.
43. Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-185.
44. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, et al. Impact of proges-togens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2004;2:1594-1600.
45. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81: 482-490.
46. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010;126:5-11.
47. Hoibraaten E, Mowinckel MC, de Ronde H, et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001; 115:415-420.
48. Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001;135: 322-327.
49. Canonico M, Alhenc-Gelas M, Plu-Bureau G, et al. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of the progestogen. Menopause 2010;17:1122-1127.
50. Curvers J, Thomassen MC, Rimmer J, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002;88:5-11.
51. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmeno-pausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-1121.
52. Oger E, Alhenc-Gelas M, Lacut K, et al; SARAH Investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-1676.
53. Scarabin PY, Oger E, Plu-Bureau G; Estrogen and Thromboembolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
54. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
55. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
56. Canonico M, Oger E, Plu-Bureau G, et al; Estrogen and Thromboem-bolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.